Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Volatiliteit in paranoia (VIP)

25 september 2026 bijgewerkt door: Julia Sheffield, Vanderbilt University Medical Center

Het testen van de rol van overtuiging bijwerken bij vervolgingswaanideeën

The goal of this clinical trial is to learn whether learning and belief updating change in response to the treatment of persecutory delusions, in individuals with schizophrenia-spectrum disorders.

The main questions are:

  1. do prior expectations about environmental volatility reduce following effective psychotherapeutic treatment of delusions?
  2. does corresponding brain activity related to volatility change with effective treatment of delusions?

Participants will:

  1. engage in CBTp or TAU + phone check-ins for 16 weeks
  2. complete assessments at 4 timepoints over the course of 6 months
  3. complete an MRI when possible

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

120

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37212
        • Werving
        • Vanderbilt University Medical Center
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Men and women age 18 - 65.
  • Communicative in English.
  • Premorbid IQ >79 (WTAR)
  • Provide voluntary, written informed consent.
  • Stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication.
  • Diagnosis of a non-affective psychotic disorder (e.g. schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder)
  • A persecutory delusion scoring at least a 3 on the conviction scale of the Psychotic Symptoms Rating Scale (PSYRATS) that had persisted for at least two months and that was not considered the direct result of substance use.

Exclusion Criteria:

  • Serious medical or neurological illness known to interfere with cognitive functioning (uncontrolled/unstable diabetes, uncontrolled hypothyroidism, Cushing's disease, Lupus, any demyelinating disease such as Multiple Sclerosis, HIV infection, CNS infection, unstable heart disease, active hepatitis, other significant endocrine condition, any cancer involving the CNS/brain, any uncorrected vision problems, tardive dyskinesia).
  • History of severe head trauma with loss of consciousness >30 minutes.
  • Primary diagnosis of alcohol or substance use disorder or personality disorder

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: CBTp

Weekly individual psychotherapy targeting specific maintenance factors of paranoia (worry, anomalous experiences, self-confidence, and safety behaviors), tailored to the participant's experience

Individuals will be assessed for which psychological factors are maintaining paranoia in their daily lives. They will collaboratively identify one maintenance factor to focus on (e.g. worry, anomalous experience, self-confidence, PTSD) for 8 weeks of individual therapy. Then, all participants will transition to 8 weeks of individual therapy focused on dropping safety behaviors and re-engaging in everyday life.

Actieve vergelijker: TAU + Phone Check-In

Participants will continue with their regular care (treatment as usual (TAU)) without interference from the study team. In addition to TAU, a study therapist will call them weekly to review what treatment the participants have engaged in. Phone calls will last approximately 5-10 minutes

Individuals will continue treatment as usual (TAU). In addition they will have contact with a study therapist weekly via phone to provide information on what treatment they received. Phone check-ins will last approximately 5-10 minutes.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in prior expectations of volatility (mu3)
Tijdsspanne: Baseline to 16 weeks

Reversal learning data will be collected from a 3-option probabilistic reversal learning task. This data will be analyzed using a computational model that estimates the prior expectations of environmental volatility. That parameter, in many models, is Mu3.

Baseline to 16 weeks
Change in unexpected uncertainty (kappa)
Tijdsspanne: Baseline to 16 weeks

Reversal learning data will be collected from a 3-option probabilistic reversal learning task. This data will be analyzed using a computational model that estimates the unexpected uncertainty, sometimes also referred to as sensitivity to volatility.

Baseline to 16 weeks
Change in psychotic Symptom Rating Scale (PSYRATS)- Belief Subscale Total
Tijdsspanne: Baseline to 16 weeks

The PSYRATS is a interview-assisted assessment measuring the severity of a delusional belief. Total scores range from 0-24 with high scores indicating more severe delusion; 6 questions, 0-4 scale for each item

Baseline to 16 weeks
Change in PANSS Positive Symptoms - Total
Tijdsspanne: Baseline to 16 weeks

The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score for each participant was sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. The positive symptom total score is the sum of the Positive Symptom items

Baseline to 16 weeks
BOLD activation change during PRL task, pre/post treatment - prefrontal cortex
Tijdsspanne: Baseline to 16 weeks

functional MRI will be used to collect BOLD activation data during the PRL reversal learning task. The investigators expect changes in activation following treatment, particularly in the CBTp group

Baseline to 16 weeks
BOLD activation change pre/post treatment - striatum
Tijdsspanne: Baseline to 16 weeks

functional MRI will be used to collect BOLD activation data during the PRL reversal learning task. The investigators expect changes in activation following treatment, particularly in the CBTp group

Baseline to 16 weeks
BOLD activation change during PRL task, pre/post treatment - locus coeruleus
Tijdsspanne: Baseline to 16 weeks

functional MRI will be used to collect BOLD activation data during the PRL reversal learning task. The investigators expect changes in activation following treatment, particularly in the CBTp group

Baseline to 16 weeks
Task-based functional connectivity changes during PRL task, pre/post treatment - prefrontal cortex to striatum
Tijdsspanne: Baseline to 16 weeks

Functional connectivity during the PRL task will be quantified between the dlPFC and striatum

Baseline to 16 weeks
Volatility Expectations - During Stable3 Task
Tijdsspanne: Change from baseline
Change from baseline
Scale of Unpredictability Beliefs
Tijdsspanne: Change from baseline
Change from baseline

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Vetgedrukte activeringswijzigingen tijdens PRL -taak, pre/post -behandeling - gehele hersenanalyse
Tijdsspanne: Basislijn tot 16 weken
Basislijn tot 16 weken
Change in PANSS P1 Item
Tijdsspanne: Baseline to 16 weeks

The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score for each participant was sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. P1 is the first item on the scale, representing delusion severity

Baseline to 16 weeks
Change in PANSS P6 Item
Tijdsspanne: Baseline to 16 weeks

The PANSS is a 30-item clinician-rated instrument for assessing schizophrenia symptoms. It consists of 3 subscales: positive subscale (7 items), negative subscale (7 items), and general psychopathology subscale (16 items). For each item, symptom severity was rated on a 7-point scale, from 1=absent to 7=extreme. The PANSS total score for each participant was sum of the rating assigned to each of the 30 PANSS items, and ranged from 30 to 210 with a higher score indicating greater severity of symptoms. P6 is the item on the scale assessing severity of paranoia/suspiciousness

Baseline to 16 weeks
Change in meta-volatility learning rate (omega3)
Tijdsspanne: Baseline to 16 weeks

Reversal learning data will be collected from a 3-option probabilistic reversal learning task. This data will be analyzed using a computational model that estimates the meta-volatility.

Baseline to 16 weeks
PSYRATS Hallucinations
Tijdsspanne: Change from baseline
Change from baseline
Kamin Blocking
Tijdsspanne: Change from baseline
Change from baseline
Social Hallucinations - Chasing
Tijdsspanne: Change from baseline
Change from baseline
Minnesota Trust Game
Tijdsspanne: Change from baseline
Change from baseline
r-GPTS
Tijdsspanne: Change from baseline
Change from baseline
DWQ
Tijdsspanne: Change from baseline
Change from baseline
BDI-II
Tijdsspanne: Change from baseline
Change from baseline
O-AS
Tijdsspanne: Change from baseline
Change from baseline
Positive Thoughts Scale
Tijdsspanne: Change from baseline
Change from baseline
Guilt and Shame Experiences Scale
Tijdsspanne: Change from baseline
Change from baseline
O-CDQ
Tijdsspanne: Change from baseline
Change from baseline
Insomnia Severity Index
Tijdsspanne: Change from baseline
Change from baseline
PCL-5
Tijdsspanne: Change from baseline
Change from baseline
CEFSA
Tijdsspanne: Change from baseline
Change from baseline
DERS-16
Tijdsspanne: Change from baseline
Change from baseline
Intolerance of Uncertainty
Tijdsspanne: Change from baseline
Change from baseline
LSAS
Tijdsspanne: Change from baseline
Change from baseline
LSNS-6
Tijdsspanne: Change from baseline
Change from baseline
CHOICE
Tijdsspanne: Change from baseline
Change from baseline
WEMWBS
Tijdsspanne: Change from baseline
Change from baseline
MCQ-36
Tijdsspanne: Change from baseline
Change from baseline

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 januari 2025

Primaire voltooiing (Geschat)

3 september 2029

Studie voltooiing (Geschat)

1 februari 2030

Studieregistratiedata

Eerst ingediend

12 februari 2025

Eerst ingediend dat voldeed aan de QC-criteria

12 februari 2025

Eerst geplaatst (Werkelijk)

19 februari 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 september 2026

Laatste update ingediend die voldeed aan QC-criteria

25 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren